All In Biotech

NDA 215143 · Hikma

Succinylcholine Chloride

Succinylcholine Chloride · Intramuscular, Intravenous

Discontinued

Last checked: Nov 20, 2026Latest source record: Nov 1, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Aug 20, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

64

13 Phase 3, 4 recruiting

FAERS reports

2,012

1,725 serious, 234 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 20, 2021 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • SUCCINYLCHOLINE CHLORIDE · SUCCINYLCHOLINE CHLORIDE 100MG/5ML (20MG/ML) · SOLUTION, INTRAMUSCULAR, INTRAVENOUS · Discontinued · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Succinylcholine Chloride" as an intervention, any sponsor and status, largest first.

All 64 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective232
  • hypotension177
  • cardiac arrest160
  • anaphylactic shock146
  • drug interaction126
  • anaphylactic reaction111
  • renal failure99
  • renal impairment99
  • hyperthermia malignant98
  • pain96
  • maternal exposure during pregnancy91
  • injury87

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200491
200529
200640
200748
200844
200954
201071
2011190
201290
201327
201422
201544
201667
201793
201885
2019148
2020148
2021125
2022124
2023122
2024105
2025159
202686

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.